You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2026

Bulk Pharmaceutical API Sources for sulfinpyrazone


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for sulfinpyrazone

Vendor Vendor Homepage Vendor Sku API Url
Molport ⤷  Start Trial MolPort-003-666-286 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-13602 ⤷  Start Trial
TimTec ⤷  Start Trial SBB058184 ⤷  Start Trial
TimTec ⤷  Start Trial ST51015125 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for Sulfinpyrazone

Last updated: February 25, 2026

Who are the primary suppliers of sulfinpyrazone API?

Several pharmaceutical manufacturers globally produce sulfinpyrazone API, primarily in India, China, and a few European countries. These suppliers range from large-scale API producers to contract manufacturing organizations (CMOs).

What are the key API producers of sulfinpyrazone?

Manufacturer Location Certification Production Capacity Note
Hetero Labs Ltd. India cGMP, ISO High Known for generic APIs, including sulfinpyrazone
RuiYi (Jiangsu) Bio-Pharm China cGMP, ISO Moderate Supplies APIs for global markets
Aarti Drugs Ltd. India cGMP, ISO Moderate Focus on APIs for cardiovascular drugs
Zhejiang Hisun Pharmaceuticals China cGMP, ISO High Large-scale API manufacturing

How are API sourcing dynamics shifting?

  • Quality Standards: Suppliers must meet cGMP, ISO, and other regulatory requirements for markets such as US, EU, and Japan.
  • Regulatory Approvals: APIs from suppliers with approved DMFs or CEPs reduce market entry risks.
  • Manufacturing Capacity: Capacity expansion, especially by Indian and Chinese suppliers, influences supply stability.
  • Pricing Trends: Cost competitiveness varies; Indian suppliers typically offer lower prices, while Chinese and European suppliers maintain higher benchmarks.

What regulatory considerations impact API sourcing?

  • FDA and EMA approvals: APIs with approved Drug Master Files (DMFs) reduce regulatory hurdles.
  • International standards: Suppliers adhering to ISO 9001, ISO 14001, and cGMP are preferred.
  • Quality audits: Inspection history influences supplier selection.
  • Traceability and Documentation: Critical for ensuring compliance with pharmacopoeial requirements.

How do global trade policies influence API sourcing?

  • Tariffs and trade restrictions: Recent US-China tensions and trade policies can affect Chinese API imports.
  • Import bans: Some regions restrict API imports from certain geographic sources unless fully compliant.
  • Export controls: Chinese and Indian governments enforce export regulations impacting supply continuity.

What are the emerging sourcing trends?

  • Local manufacturing: Some companies explore regional API production to reduce supply chain vulnerabilities.
  • Vertical integration: Larger pharmaceutical firms acquire API suppliers or build in-house capacity.
  • API quality innovation: Improved synthesis routes and purification techniques enhance API purity and reduce costs.

Industry standards and APIs supply chain

Aspect Details
Quality Certifications cGMP, ISO 9001, EU GMP, US FDA DMF
Lead Times Typically 3-6 months from order to delivery
Supply Chain Risks Reliance on limited suppliers increases risk
Supplier Audits Regular audits are critical for compliance

Final notes

The API market for sulfinpyrazone remains concentrated, with primary suppliers situated in Asia. Market entrants depend heavily on supplier quality certifications, capacity, and regulatory compliance to mitigate supply chain risks. Sourcing strategies increasingly favor suppliers with established regulatory approval history to ensure uninterrupted supply and compliance with international standards.


Key Takeaways

  • Major API producers are Hetero Labs (India), RuiYi (China), Aarti Drugs (India), and Zhejiang Hisun (China).
  • Regulatory approval and quality certifications are critical for market approval.
  • Supply chain disruptions are mitigated through diversification and vertical integration.
  • Pricing varies significantly between Indian (~lower cost), Chinese, and European sources.
  • Chinese suppliers face export regulation risks, influencing global sourcing decisions.

Frequently Asked Questions

  1. What are the primary quality standards for sulfinpyrazone API?
    Suppliers primarily meet cGMP, ISO 9001, and regional standards like EU GMP and US FDA DMF requirements.

  2. How do trade restrictions impact API sourcing?
    Tariffs, trade tensions, and export bans can delay shipments or restrict access, especially from China and India.

  3. What are the typical lead times for sulfinpyrazone API orders?
    Lead times range from 3 to 6 months, influenced by supplier capacity and regulatory compliance requirements.

  4. Are there regional differences in API pricing?
    Indian suppliers generally offer lower prices compared to Chinese and European sources, which often meet higher regulatory standards.

  5. How critical is supplier auditing in API sourcing?
    Inspections ensure compliance with quality and regulatory standards, reducing risk of recalls or market access issues.


References

[1] U.S. Food and Drug Administration. (2022). Drug Master Files (DMFs). https://www.fda.gov/drugs/drug-submissions filings-and-records/drug-master-files

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.